Companies › BLTE

BELITE BIO INC (BLTE)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001889109 · EDGAR filings · Updated 2026-06-22

BELITE BIO INC (BLTE) has reported institutional ownership of 23.2%, with 75 institutional managers holding positions valued at $1.42B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Latest updates

• 2026-06-22 — Insider transaction reported (Form 4)
• 2026-06-18 — Notice of proposed sale filed (Form 144)
• 2026-06-17 — Insider transaction reported (Form 4)
• 2026-06-16 — Notice of proposed sale filed (Form 144)
• 2026-06-15 — Foreign issuer report (6-K) filed
• 2026-05-20 — Foreign issuer report (6-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BELITE BIO INC has 75 institutional holders and institutional ownership of 23.2%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 6 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

ATRICURE INC (ATRC) · DAMORA THERAPEUTICS INC (DMRA) · MONTE ROSA THERAPEUTICS INC (GLUE) · INTELLIA THERAPEUTICS INC (NTLA) · Procept Biorobotics Corp (PRCT) · BICARA THERAPEUTICS INC (BCAX)